Benzinga | Nov 10, 2020 09:36AM EST

Credit Suisse Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $42

Credit Suisse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Neutral and lowers the price target from $60 to $42.